Mingshan Cheng

809 total citations
27 papers, 541 citations indexed

About

Mingshan Cheng is a scholar working on Oncology, Immunology and Biotechnology. According to data from OpenAlex, Mingshan Cheng has authored 27 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Immunology and 8 papers in Biotechnology. Recurrent topics in Mingshan Cheng's work include Cancer Research and Treatments (8 papers), CAR-T cell therapy research (8 papers) and Cancer Cells and Metastasis (6 papers). Mingshan Cheng is often cited by papers focused on Cancer Research and Treatments (8 papers), CAR-T cell therapy research (8 papers) and Cancer Cells and Metastasis (6 papers). Mingshan Cheng collaborates with scholars based in United States, United Kingdom and Germany. Mingshan Cheng's co-authors include James Keck, Michael A. Brehm, Li‐Chin Yao, Leonard D. Shultz, Dale L. Greiner, Chong-xian Pan, Susan Airhart, Danying Cai, Karolina Palucka and Jacques Banchereau and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Mingshan Cheng

23 papers receiving 527 citations

Peers

Mingshan Cheng

ONCOL

IMMUN

PRM

Brian M. Olson United States

Yunxin Lai China

Jiemiao Hu United States

Hans Anton Schloesser Germany

Gesa Schuebbe Germany

Tatiana S. Gerashchenko Russia

Kerstin Schlüter Germany

Laura McOlash United States

Changqing Xie United States

Henrik Jespersen Sweden

Brian M. Olson United States

Mingshan Cheng

321 ×1.0

ONCOL

308 ×1.8

IMMUN

167 ×1.1

95 ×0.8

PRM

62 ×0.7

Citations per year, relative to Mingshan Cheng Mingshan Cheng (= 1×) peers Brian M. Olson

Countries citing papers authored by Mingshan Cheng

Since Specialization

Citations

This map shows the geographic impact of Mingshan Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingshan Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingshan Cheng more than expected).

Fields of papers citing papers by Mingshan Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingshan Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingshan Cheng. The network helps show where Mingshan Cheng may publish in the future.

Co-authorship network of co-authors of Mingshan Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Mingshan Cheng. A scholar is included among the top collaborators of Mingshan Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingshan Cheng. Mingshan Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Skelly, Daniel A., Mingshan Cheng, Mayuko Furuta, et al.. (2025). Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response. Cell Reports. 44(5). 115698–115698. 2 indexed citations

Yang, Hongyuan, et al.. (2023). A novel tumor-bearing humanized mouse model for evaluating the efficacy and predictive safety of bispecific T cell engager. The Journal of Immunology. 210(Supplement_1). 230.18–230.18.

Yang, Jiwon, Jing Jiao, Kyle Draheim, et al.. (2023). Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model. The FASEB Journal. 37(6). e22995–e22995. 10 indexed citations

Yao, Li‐Chin, Danying Cai, Mingshan Cheng, et al.. (2023). Abstract 6354: A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodies. Cancer Research. 83(7_Supplement). 6354–6354.

Lee, Won, et al.. (2022). In Vivo PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Autologous and Allogeneic Chimeric Antigen Receptor T-Cell Immunotherapy. Blood. 140(Supplement 1). 10267–10268.

Jiao, Jing, Chunting Ye, Danying Cai, Mingshan Cheng, & James Keck. (2020). Abstract 4512: Mouse model for in vivo evaluation of efficacy and potential cytokine release syndrome of chimeric antigen receptor (CAR) T cell therapy. Cancer Research. 80(16_Supplement). 4512–4512. 3 indexed citations

Yao, Li‐Chin, Mingshan Cheng, Leonard D. Shultz, & James Keck. (2020). Abstract 5619: PBMC humanized NSG-(KbDb)null (IA)null mouse model to evaluate immune-oncology drug efficacy. Cancer Research. 80(16_Supplement). 5619–5619. 1 indexed citations

Yang, Jiwon, et al.. (2020). Effects of aging on immunosenescence and checkpoint inhibitor efficacy in a C57BL/6J syngeneic model. The Journal of Immunology. 204(1_Supplement). 165.46–165.46.

Draheim, Kyle, Jing Jiao, Jiwon Yang, et al.. (2020). An in vivo model to evaluate donor-dependent cytokine release in response to single-agent or combination immune-oncology therapies.. Journal of Clinical Oncology. 38(15_suppl). 3114–3114. 1 indexed citations

10.

Yao, Li‐Chin, Mingshan Cheng, Leonard D. Shultz, et al.. (2020). Abstract B72: Humanized NSG-Tg(Hu-IL15) mice support preclinical immune-oncology efficacy for testing of NK cell-based immunotherapy. Cancer Immunology Research. 8(3_Supplement). B72–B72. 1 indexed citations

11.

Yao, Li‐Chin, et al.. (2019). Creation of PDX-Bearing Humanized Mice to Study Immuno-oncology. Methods in molecular biology. 1953. 241–252. 47 indexed citations

12.

Floc’h, Nicolas, Matthew J. Martin, Jonathan W. Riess, et al.. (2018). Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Molecular Cancer Therapeutics. 17(5). 885–896. 85 indexed citations

13.

Yao, Li‐Chin, Mingshan Cheng, Ken‐Edwin Aryee, et al.. (2018). Abstract 5676: Patient-derived tumor xenografts in humanized NSG-SGM3 mice: An improved immuno-oncology platform. Cancer Research. 78(13_Supplement). 5676–5676. 1 indexed citations

14.

Κατσιαμπούρα, Αναστασία, Kanwal Raghav, Zhi-Qin Jiang, et al.. (2017). Modeling of Patient-Derived Xenografts in Colorectal Cancer. Molecular Cancer Therapeutics. 16(7). 1435–1442. 38 indexed citations

15.

Riess, Jonathan W., Nicolas Floc’h, Matthew W. Martin, et al.. (2017). Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.. Journal of Clinical Oncology. 35(15_suppl). 9030–9030. 5 indexed citations

16.

Zhang, Hongyong, Yuanpei Li, Tzu‐yin Lin, et al.. (2016). Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 27(42). 425103–425103. 29 indexed citations

17.

Keck, James, Mingshan Cheng, Danying Cai, et al.. (2015). Abstract LB-050: Patient-derived tumor xenografts in humanized NSG mice: a model to study immune responses in cancer therapy. Cancer Research. 75(15_Supplement). LB–50. 1 indexed citations

18.

Yao, Li‐Chin, Mingshan Cheng, Jacques Banchereau, et al.. (2015). Abstract LB-C01: Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform. Molecular Cancer Therapeutics. 14(12_Supplement_2). LB–C01. 2 indexed citations

19.

Wang, Zhuo, John C. Donaldson, Hong Yao, et al.. (2009). Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug.. PubMed. 29(10). 3845–55. 4 indexed citations

20.

Cheng, Mingshan, Steven R. Schow, Vara Prasad Manchem, et al.. (2004). In vitro and in vivo prevention of HIV protease inhibitor‐induced insulin resistance by a novel small molecule insulin receptor activator. Journal of Cellular Biochemistry. 92(6). 1234–1245. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact